Sept. 10 - 13, 2023

25th North America ISSX Meeting

  • days
  • Hours
  • Minutes
  • Seconds

BOOTH

#401

Industry-Sponsored Symposium

Sept. 13, 7:15 - 8:15 AM
BioIVT at the 25th North American ISSX Meeting

BioIVT is proud to be a sponsor at this year’s 25th North American ISSX Meeting, which will take place September 10 – 13 in Boston, Massachusetts.
We will also be presenting on several topics, including:

  • The global ICH DDI Guideline
  • Donor diversity impacts on test system activity
  • Monocarboxylate Transporter 10
  • Inhibition assay with rat CYP3A enzymes

We are excited to have the opportunity to share with you and other industry leaders how we can help accelerate your ADME research. Meet with our team to learn more about how we support drug R&D programs:

  • Comprehensive portfolio of products used to support ADME-Tox research
  • Global logistics infrastructure that ensures you receive the hepatic products you need when you need them.
  • ADME-Tox research services designed to help optimize your research programs based on your specific goals.
  • Consulting support to develop ADME strategies focused on clients’ objectives

Would you like a copy of our presentations?

Whether or not you are attending ISSX this year, we can send you links to all of our scientific content from the event. Click on the button below to register.

Request Access Now

CONFERENCE SCHEDULE

12:00 - 3:00 PM

Exhibit

Stop by Booth 401 to learn more about how we support drug R&D programs:

  • Comprehensive portfolio of products used to support ADME-Tox research
  • Global logistics infrastructure that ensures you receive the hepatic products you need when you need them.
  • ADME-Tox research services designed to help optimize your research programs based on your specific goals.
  • Consulting support to develop ADME strategies focused on clients’ objectives

As the unparalleled leader in providing human and animal hepatocytes, NPCs, and subcellular fractions for all in vitro ADME-Tox models along with unparalleled expertise in providing in vitro ADME services, BioIVT is a trusted partner for your ADME research needs.

12:00 - 2:30 PM

Exhbit

Stop by Booth 401 to learn more about how we support drug R&D programs:

  • Comprehensive portfolio of products used to support ADME-Tox research
  • Global logistics infrastructure that ensures  you receive the hepatic products you need when you need them.
  • ADME-Tox research services designed to help optimize your research programs based on your specific goals.
  • Consulting support to develop ADME strategies focused on clients’ objectives

As the unparalleled leader in providing human and animal hepatocytes, NPCs, and subcellular fractions for all in vitro ADME-Tox models along with unparalleled expertise in providing in vitro ADME services, BioIVT is a trusted partner for your ADME research needs.

12:00 - 2:30 PM

Poster Sessions

P27: Impact of Donor Diversity on Phase I and Phase II Activities in Cryopreserved Hepatocytes and Human Liver Microsomes
Presentation Times: Sept. 12, 12:30-1:30 PM
Presented By: Chris Bohl, PhD, Scientific Advisor, Products, BioIVT

P23: Development of a Simple, Fast Inhibition Assay for Rat CYP3A Enzymes
Presentation Times: Sept. 12, 12:30-1:30 PM
Presented By: Michael Voice, PhD, General Manager, Operations, BioIVT

7:15 - 8:15 AM

Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies M12 Guideline and Comparison with Current Guidance

Abstract: In June 2022, the ICH released the draft of its harmonized Drug Interaction Studies Guideline (M12).  The guideline resulted from several meetings of the Expert Working Group since 2018 with the goal of harmonizing member regulatory agencies’ guidelines into one that will be used across all member countries. After review, the guideline will be adopted in 2024. This presentation will describe differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan on meeting the ICH M12 guideline.

Brian Ogilvie, PhD, / VP of Scientific Consulting at BioIVT
12:00 - 2:30 PM

Poster Presentations

P179: Monocarboxylate Transporter 10: Substrate-Dependent Mode of Transport
Presentation Times: Sept. 13, 12:30–1:30 PM
Presented By: Mark Warren, PhD, Senior Dir. of Transporter Assay Services, BioIVT

Our scientific teams and business development representatives will be at ISSX to discuss how our comprehensive portfolio of hepatic products and ADME-Tox research services can accelerate your research.

Mark Warren, PhD
Senior Director, Transporter Assay Services
Chris Bohl
Senior Manager Technical Support
Michael Voice
General Manager
Robert Taylor, PhD
Director, TSS, ADMET
Andrew Taylor, PhD
Technical Sales Specialist, ADMET
Matthew Shaw, MSc
Business Development Manager
Andrew Santos
Business Development Manager
Graham Dyck
Director of Marketing, ADME-Tox
Brian Ogilvie, PhD
VP of Scientific Consulting
Rachel Whisnant
Business Development Manager
Meet with an Expert

Scientific Presentation

Dr. Brian Ogilvie, Vice President, Scientific Consulting will be presenting ‘Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies Guideline and Comparison with Current Guidance’. The presentation will highlight changes in the new guidance and provide recommendations on how in vitro ADME should be updated to ensure sponsors have the data required for IND submissions.

Discover the Details

Resources

AT_Trusted Provider_VID

Watch this video to learn why BioIVT is your trusted partner for drug discovery and ADME-Tox in vitro models. 

 

Watch Now
AT_XT Consulting_Cover

Learn more about XENOTECH Consulting Services at BioIVT. Our experts help researchers optimize in vitro research programs and ensure data packages are ready for regulatory submissions. Download our brochure to learn more.

Download Now
AT_Tiers WBR

BioIVT has developed new, tiered in vitro ADME study options to match quality, timeline, and cost needs with individual client programs. Download the slides and recording from this webinar to learn more.

Download Now